Reminder of Important Clinical Lesson: Irritable Bowel Syndrome in Primary Care Physicians
Main Article Content
Abstract
Irritable bowel syndrome (IBS) is one of the most commonly diagnosed gastrointestinal diseases. IBS, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of IBS is broad and not clearly understood. Nearly 12 percent of patients seek medical care in primary care practices for IBS related complaints. The pathophysiology of IBS is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress. The clinical case presented has the textual characteristics that represent treating a patient with diagnostic criteria for this pathology. Presenting prevalent cases helps the physician in training and specialists not to overlook what is common in clinical practice.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Enck P, Aziz Q, Barbara G, Farmer A, Fukudo S, Mayer E, Niesler B, Quigley E, Rajilic-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller R. Irritable bowel syndrome (IBS). Nat Rev Dis Primers. 2016;2:16014.
II. Fukudo, S., Okumura, T., Inamori, M. et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56, 193–217 (2021). https://doi.org/10.1007/s00535-020-01746-z
III. Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., Whitehead, W. E., Dumitrascu, D. L., Fang, X., Fukudo, S., Kellow, J., Okeke, E., Quigley, E. M. M., Schmulson, M., Whorwell, P., Archampong, T., Adibi, P., Andresen, V., Benninga, M. A., Bonaz, B., … Palsson, O. S. (2021). Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 160(1), 99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
IV. Tan ZE, Tan YQ, Lin H, How CH. Irritable bowel syndrome: an approach for primary care physicians. Singapore Med J. 2022 Jul;63(7):367-370. doi: 10.4103/0037-5675.354224. PMID: 36074566; PMCID: PMC9578123.
V. Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M., Rajilić-Stojanović, M., Schemann, M., Schwille-Kiuntke, J., Simren, M., Zipfel, S., & Spiller, R. C. (2016). Irritable bowel syndrome. Nature reviews. Disease primers, 2, 16014. https://doi.org/10.1038/nrdp.2016.14
VI. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19:861–70.
VII. Ohman L, Stridsberg M, Isaksson S, et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol. 2012;107:440–7.
VIII. Hernández-Velásquez, D.A., Rodríguez-Martínez, E., Montoya-Meneses, J.D. et al. Clinical Characteristics and Treatment of Irritable Bowel Syndrome in a Colombian Population: A Cross-Sectional Study. Drugs - Real World Outcomes 10, 651–658 (2023). https://doi.org/10.1007/s40801-023-00395-x
IX. Molina-Infante, J., Serra, J., Fernandez-Bañares, F., & Mearin, F. (2016). The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. Gastroenterologia y hepatologia, 39(2), 55–65. https://doi.org/10.1016/j.gastrohep.2015.07.009
X. Gómez Alvarez, D. F., Morales Vargas, J. G., Rojas Medina, L. M., Mújica Oviedo, S. C., Camacho López, P. A., & Rueda Jaimes, G. E. (2009). Factores sociosanitarios y prevalencia del síndrome del intestino irritable según los criterios diagnósticos de Roma III en una población general de Colombia [Prevalence of irritable bowel syndrome and associated factors according to the Rome III diagnostic criteria in a general population in Colombia]. Gastroenterologia y hepatologia, 32(6), 395–400. https://doi.org/10.1016/j.gastrohep.2009.01.177
XI. Palsson, O. S., Whitehead, W., Törnblom, H., Sperber, A. D., & Simren, M. (2020). Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology, 158(5), 1262–1273.e3. https://doi.org/10.1053/j.gastro.2019.12.021
XII. Dothel, G., Barbaro, M.R., Di Vito, A. et al. New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics. J Gastroenterol 58, 605–621 (2023). https://doi.org/10.1007/s00535-023-01997-6
XIII. Drossman, D. A., & Hasler, W. L. (2016). Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 150(6), 1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035
XIV. Ng, Q. X., Soh, A. Y. S., Loke, W., Venkatanarayanan, N., Lim, D. Y., & Yeo, W. S. (2019). Systematic review with meta-analysis: The association between post-traumatic stress disorder and irritable bowel syndrome. Journal of gastroenterology and hepatology, 34(1), 68–73. https://doi.org/10.1111/jgh.14446
XV. Videlock, E. J., Adeyemo, M., Licudine, A., Hirano, M., Ohning, G., Mayer, M., Mayer, E. A., & Chang, L. (2009). Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology, 137(6), 1954–1962.
https://doi.org/10.1053/j.gastro.2009.08.058
XVI. Stasi, C., Bellini, M., Bassotti, G., Blandizzi, C., & Milani, S. (2014). Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Techniques in coloproctology, 18(7), 613–621. https://doi.org/10.1007/s10151-013-1106-8
XVII. Sun, S., Chen, J., Li, H. et al. Patients’ perspectives on irritable bowel syndrome: a qualitative analysis based on social media in China. Qual Life Res 32, 2561–2571 (2023). https://doi.org/10.1007/s11136-023-03417-x
XVIII. Fukudo, S., Okumura, T., Inamori, M. et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56, 193–217 (2021). https://doi.org/10.1007/s00535-020-01746-z
XIX. Lackner, J. M., Mesmer, C., Morley, S., Dowzer, C., & Hamilton, S. (2004). Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. Journal of consulting and clinical psychology, 72(6), 1100–1113.
https://doi.org/10.1037/0022-006X.72.6.1100
XX. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut. 2003 Nov;52(11):1623-9. doi: 10.1136/gut.52.11.1623. PMID: 14570733; PMCID: PMC1773844.
XXI. Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V. Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag. 2015 May 30;11:691-703. doi: 10.2147/TCRM.S54298. PMID: 26028974; PMCID: PMC4425337.
XXII. Khanna, R., MacDonald, J. K., & Levesque, B. G. (2014). Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Journal of clinical gastroenterology, 48(6), 505–512. https://doi.org/10.1097/MCG.0b013e3182a88357
XXIII. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009 Apr 7;15(13):1548-53. doi: 10.3748/wjg.15.1548. PMID: 19340896; PMCID: PMC2669938.
XXIV. Madia, V. N., Messore, A., Saccoliti, F., Tudino, V., De Leo, A., De Vita, D., Bortolami, M., Scipione, L., Pindinello, I., Costi, R., & Di Santo, R. (2020). Tegaserod for the Treatment of Irritable Bowel Syndrome. Anti-inflammatory & anti-allergy agents in medicinal chemistry, 19(4), 342–369.
https://doi.org/10.2174/1871523018666190911121306
XXV. Lembo, T., Wright, R. A., Bagby, B., Decker, C., Gordon, S., Jhingran, P., Carter, E., & Lotronex Investigator Team (2001). Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. The American journal of gastroenterology, 96(9), 2662–2670.